Managing immunogenicity risk should be a core focus in drug development. ProImmune’s CEO Nik Schwabe explains why.
Dr Nikolai Schwabe introduces the ProPresent antigen presentation assay and some of its applications in the field of immunogenicity.
Dr Briana Betz explains the importance of understanding the HLA types of your study cohort, and how ProImmune can help you.
Dr Heather Hensler introduces ProArray Ultra®, the high-throughput peptide and protein microarray assay service.
Dr Andrew Waller provides an overview of the Pro5 Pentamer technology and the benefits of using MHC pentamers to detect specific CD8 T Cell populations in your research.
Dr Jeremy Fry provides a summary of ProImmune’s REVEAL and ProVE® service, the rapid epitope discovery system.